Prime Medicine (PRME) Profit After Tax (2021 - 2026)

Prime Medicine (PRME) has 6 years of Profit After Tax data on file, last reported at -$49.2 million in Q1 2026.

• Quarterly Profit After Tax rose 5.2% year-over-year to -$49.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$198.4 million (up 1.81% YoY) and the FY2025 annual result came in at -$201.1 million, down 2.64% from the prior year.
• Profit After Tax declined to -$49.2 million in Q1 2026, from -$46.0 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of -$23.8 million in Q1 2022 to a low of -$65.5 million in Q4 2023.
• A 5-year average of -$46.2 million and a median of -$49.2 million in 2026 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2022 — Profit After Tax sank 78.83% — and 2024, when it soared 35.47%.
• Tracing PRME's Profit After Tax over 5 years: stood at -$59.5 million in 2022, then fell by 10.14% to -$65.5 million in 2023, then jumped by 35.47% to -$42.3 million in 2024, then decreased by 8.8% to -$46.0 million in 2025, then decreased by 6.97% to -$49.2 million in 2026.
• The last three Profit After Tax figures came in at -$49.2 million (Q1 2026), -$46.0 million (Q4 2025), and -$50.6 million (Q3 2025), per Business Quant data.